390
Participants
Start Date
November 10, 2008
Primary Completion Date
August 19, 2009
Study Completion Date
August 19, 2009
GSK Biologicals' influenza vaccine GSK1557482A
one IM injection at Day 0 for primed subjects (defined as subjects who had a prior 2-dose priming influenza immunization) or two IM injections at Day 0 and approximately Day 28 for un-primed subjects (defined as subjects who have not previously received a complete 2-dose priming influenza immunization).
Vaxigrip
one IM injection at Day 0 for primed subjects (defined as subjects who had a prior 2-dose priming influenza immunization) or two IM injections at Day 0 and approximately Day 28 for un-primed subjects (defined as subjects who have not previously received a complete 2-dose priming influenza immunization).
GSK Investigational Site, Calgary
GSK Investigational Site, Langley
GSK Investigational Site, Winnipeg
GSK Investigational Site, Mount Pearl
GSK Investigational Site, Halifax
GSK Investigational Site, Greater Sudbury
GSK Investigational Site, Hamilton
GSK Investigational Site, London
GSK Investigational Site, London
GSK Investigational Site, Mississauga
GSK Investigational Site, Newmarket
GSK Investigational Site, Sarnia
GSK Investigational Site, Toronto
GSK Investigational Site, Charlottetown
GSK Investigational Site, Montreal
GSK Investigational Site, Québec
GSK Investigational Site, Ste-Foy
GSK Investigational Site, Trois-Rivières
Lead Sponsor
GlaxoSmithKline
INDUSTRY